COMMUNIQUÉS West-GlobeNewswire

Balt’s Squid™ Liquid Embolic Receives FDA Approval for Adjunctive Treatment for Patients with Chronic Subdural Hematomas
04/02/2026
BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Balt, Inc., a global technology leader in neurovascular devices, today announced the Premarket Approval (PMA) of the Squid™ liquid embolic agent. Squid is approved for the [...]
Breckenridge Distillery Appoints Romano Beverage for Distribution in Illinois
04/02/2026
Award-winning spirits brand announce new distribution partner to oversee statewide distribution BRECKENRIDGE, Colo., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and [...]
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
04/02/2026
This is the third program that s uccessfully combine s Entera’s oral peptide N- Tab ® platform with OPKO ’s advanced protein chemistry capabilities The c ompanies have accelerated this program and aim to file an [...]
Pharmazz Presents Positive Phase IV Interim Analysis of Sovateltide for Acute Ischemic Stroke at the International Stroke Conference 2026
04/02/2026
WILLOWBROOK, Ill., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Pharmazz, Inc. today announced the presentation of positive interim results from its ongoing Phase IV clinical study of sovateltide (Tycamzzi®) in patients with acute [...]
Cozeva Earns 2026 Best in KLAS for Risk Adjustment: POC and In-Home Health Assessments
04/02/2026
SAN RAMON, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Cozeva, a healthcare technology company delivering a single, unified platform for value-based care, has earned the 2026 Best in KLAS distinction for Risk Adjustment: [...]
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced [...]
Imprivata Enterprise Access Management Wins 2026 Best in KLAS Award for Access Management
04/02/2026
WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Imprivata , a leading provider of access management solutions for healthcare and other mission-critical industries, today announced that Imprivata Enterprise Access [...]
Normunity to Participate in the TD Cowen 46ᵗʰ Annual Health Care Conference
04/02/2026
BOSTON and NEW HAVEN, Conn., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Normunity , a clinical stage biotechnology company pioneering precision biologics, today announced that management will participate in the TD Cowen 46 th [...]
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit
04/02/2026
NAARDEN, The Netherlands and MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
R1 Awarded ‘Best in KLAS’ Across Multiple RCM Categories for 2026
04/02/2026
Providers Recognize R1 for Unwavering Commitment to Launching Innovative Technology CHICAGO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), the leader in healthcare revenue management, has been named a [...]
The Noom Engagement Report: New Data Shows that the GLP-1 Patients Who Use Noom the Most Also Lose the Most Weight and Stay On Medication Program Longest
04/02/2026
Most-engaged members lost 25.2% more weight at week 40 and persisted 2.2x longer on medication program than least-engaged members using the Noom app, demonstrating the benefits of combining GLP-1 medication with Noom’s [...]
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™
04/02/2026
Real-world and clinical trial data underscore long-term safety and effectiveness in pediatric and adult NPC patients CELEBRATION, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra [...]
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
04/02/2026
Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat population Company to launch controlled study in second-line KRAS-mutant MSS mCRC with [...]
NewGen and Evident Capital Successfully Activate Commitment Campaign for Inaugural Tokenized Real Estate Bond, Delivering on Cross-Border Real World Asset Financing Strategy
04/02/2026
Rapid progress from announcement of successful launch in under two weeks signals NewGen’s expertise and commitment Launch represents fulfilment of NewGen’s goals to spearhead Real World Asset tokenization, puts Company [...]
Control the Stack, Control the Future: The New Era of Supply-Chain Power
04/02/2026
DENVER, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Innovation still rules, but ownership of the entire supply-chain pipeline is becoming the next biggest strategic advantage in today’s markets. From raw inputs to final delivery [...]
CytomX Therapeutics to Present at Upcoming February Conferences
04/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will [...]
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
04/02/2026
MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory [...]
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
04/02/2026
PRINCETON, N.J., Feb. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
04/02/2026
February 4, 2026 Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models Cardiff, UK – [...]

Pages